OBJECTIVES: To explore trends in liver transplantation (LT) and outcomes for older recipients for evaluation, counseling, and appropriate referral of this vulnerable group of older adults. DESIGN: Prospective national cohort study. SETTING: Scientific Registry of Transplant Recipients (January 1, 2003-December 31, 2016. PARTICIPANTS: Older (aged ≥ 65) deceased donor liveronly transplant recipients (n=8,627). MEASUREMENTS: We evaluated temporal changes in recipient, donor, and transplant characteristics and post-LT length of stay (LOS), acute rejection, graft loss, and mortality using logistic regression and Cox proportional hazards. RESULTS: LT in older adults almost quadrupled, from 263 in 2003 (9.5% of total LTs that year) to 1,144 in 2016 (20.7% of total LTs). Recent recipients were more likely to be female and African American and have a higher body mass index and Model for End-Stage Liver Disease score. Hepatitis C, nonalcoholic steatohepatitis, and hepatocellular carcinoma were the most common indications for LT in recent recipients. Odds of LOS longer than 2 weeks decreased 34% from 2003-06 to 2013-16 (adjusted odds ratio (aOR)=0.66, 95% confidence interval (CI)=0.57-0.76, P < .001), 1-year acute rejection decreased 30% (aOR=0.70, 95% CI=0.56-0.88, P = .002), all-cause graft loss decreased 54% (adjusted hazard ratio (aHR) =0.46, 95% CI=0.40-0.52, P < .001), and mortality decreased 57% (aHR=0.43, 95% CI=0.38-0.49, P < .001). 2,5 The aging population with hepatitis C virus cirrhosis and the increase in nonalcoholic steatohepatitis and hepatocellular carcinoma, which typically affect older adults, 3, 4, 6, 7 are driving the increase in older adults with ESLD. Historically, older adults were denied access to LT because of poor posttransplantation survival, [8] [9] [10] but there are more-recent reports of LT in older adults, including small reports of LT even in those in their 80s and older. 11, 12 It is possible that advances in immunosuppression regimens and surgical techniques 13-16 may be leading to better LT outcomes in older adults, although older adults are uniquely susceptible after LT given their greater comorbidity, prevalence of frailty, and physical impairment. [17] [18] [19] In older LT candidates and recipients, physical impairment, frailty, and older age are associated with greater risk of dying. 2, 18, [20] [21] [22] In addition, older adults have immunosenescence, leading to lower tolerance of post-LT immunosuppression. [23] [24] [25] Therefore, improvements in modern immunosuppression may not translate to better posttransplantation outcomes over time in older recipients. Furthermore, poor outcomes in older LT recipients are typically due to cardiac complications, malignancy, and infection, 8, 9, 26 so surgical and immunosuppression changes do not necessarily translate into better outcomes for older recipients. A better understanding of the trends over time in outcomes for older LT recipients is warranted for appropriate LT referral, evaluation, and counseling before transplantation.
T he burden of end-stage liver disease (ESLD) in older adults (aged ≥65) in the United States is increasing, [1] [2] [3] [4] with older adults accounting for 23.8% of the liver transplant (LT) waitlist in 2017, up from 8% in 2002. 2, 5 The aging population with hepatitis C virus cirrhosis and the increase in nonalcoholic steatohepatitis and hepatocellular carcinoma, which typically affect older adults, 3, 4, 6, 7 are driving the increase in older adults with ESLD. Historically, older adults were denied access to LT because of poor posttransplantation survival, [8] [9] [10] but there are more-recent reports of LT in older adults, including small reports of LT even in those in their 80s and older. 11, 12 It is possible that advances in immunosuppression regimens and surgical techniques [13] [14] [15] [16] may be leading to better LT outcomes in older adults, although older adults are uniquely susceptible after LT given their greater comorbidity, prevalence of frailty, and physical impairment. [17] [18] [19] In older LT candidates and recipients, physical impairment, frailty, and older age are associated with greater risk of dying. 2, 18, [20] [21] [22] In addition, older adults have immunosenescence, leading to lower tolerance of post-LT immunosuppression. [23] [24] [25] Therefore, improvements in modern immunosuppression may not translate to better posttransplantation outcomes over time in older recipients. Furthermore, poor outcomes in older LT recipients are typically due to cardiac complications, malignancy, and infection, 8, 9, 26 so surgical and immunosuppression changes do not necessarily translate into better outcomes for older recipients. A better understanding of the trends over time in outcomes for older LT recipients is warranted for appropriate LT referral, evaluation, and counseling before transplantation.
In light of the aging of the population with ESLD, we sought to evaluate and understand temporal trends in LT and post-LT outcomes for older recipients. To inform clinical practice, we used national registry data to characterize the changing landscape of LT in older adults and describe trends over the last 15 years in LT hospital length of stay (LOS), acute rejection, graft loss, and mortality for older recipients.
METHODS

Data Source
This study used data from the Scientific Registry of Transplant Recipients (SRTR) external release made available in March 2017. The SRTR data system includes data on all donors, waitlisted candidates, and transplant recipients in the United States that members of the Organ Procurement and Transplantation Network (OPTN) have submitted and has been described elsewhere. 27 Data on all-cause graft loss and mortality were augmented through linkage with the Social Security Master Death File, Centers for Medicare and Medicaid Services data, and waitlist data. The Health Resources and Services Administration, U.S. Department of Health and Human Services, oversees the activities of OPTN and SRTR contractors.
Study Population
We identified 8,627 older (≥ 65) deceased donor liver-only transplant recipients between January 1, 2003, and December 31, 2016, using data from SRTR. We grouped these recipients according to year of LT into 4 strata for empirical reasons and to reflect changes in allocation policy and general evolution of immunosuppression regimens We divided the recent time periods at June 18, 2013, to evaluate trends before and after implementation of the Share 35 policy change, which increased regional liver allograft offers to individuals with Model for End-Stage Liver Disease (MELD) scores of 35 and greater. The annual number and percentage of LTs for older recipients was examined over time. Donor, recipient, and transplantation characteristics were examined using t-tests for continuous variables and chi-square tests for categorical variables.
Outcomes
LOS was defined as the duration of hospitalization during the initial transplant episode and analyzed as a binary variable of 2 weeks or less versus more than 2 weeks using adjusted multiple logistic regression-a cut-off previously used in abdominal solid organ transplantation. 28, 29 Acute rejection within the first year after LT was analyzed as a binary variable using adjusted multiple logistic regression. All-cause graft loss and mortality were estimated at 1, 3, and 5 years using the Kaplan-Meier method for each time stratum. Kaplan-Meier methods were also used to create unadjusted cumulative incidence curves of all-cause graft loss and mortality. Cox proportional hazards models for all-cause graft loss and mortality were used to adjust for changes in recipient, donor, and transplantation characteristics. Proportional hazards assumptions were confirmed using visual inspection of complementary log-log plots and Schoenfeld residuals.
Statistical Analyses
To ensure proper risk adjustment, we adjusted each of the regression models for standard factors accounted for in the SRTR program specific reports, including recipient factors (sex, age, race, body mass index (BMI), primary diagnosis, life support, hepatocellular carcinoma, non-hepatocellular carcinoma malignancy, hepatitis C virus, human immunodeficiency virus status, diabetes, primary insurance, portal vein thrombosis, split LT) and donor factors (age, race, BMI, hepatitis C virus, donation after cardiac death, ABO compatibility, cold ischemia time). All analyses were twotailed, and α was set at .05. All analyses were performed using Stata version 14.2/MP for Linux (Stata Corp., College Station, TX).
RESULTS
Study Population
Of 58,598 adult LT recipients, 8,627 (14.7%) were aged 65 and older between 2003 and 2016; 78.0% were aged 65 to 69, 20.1% were aged 70 to 74, 1.6% were aged 75 to 79, and 0.1% were aged 80 and older; 36.1% were female; and 6.4% were black (Table 1) .
Increase in LT in Older Adults
The annual number of LTs performed in older adults increased substantially throughout the study period ( Figure 1A ). In 2016, 1,144 older adults underwent LT (20.7% of all LT recipients), up from 263 in 2003 (9.5% of all LT recipients).
Changing Landscape of LT in Older Adults
The age of LT recipients has increased over time ( Figure 1B ). Older LT recipients became more likely to be male (66.0% in 2013-16 vs 61.1% in 2003-06, P = .006), black (7.8% vs 3.9%, P < .001), have a MELD score of 30 or greater (34.2% vs 13.0%, P < .001), have portal vein thrombosis (14.6% vs 5.0%, P < .001), and have nonalcoholic steatohepatitis (19.5% vs 5.8%) or hepatocellular carcinoma (28.9% vs 18.4%) as their indication for LT (Table 1) . They also became more likely to receive a hepatitis C virus positive liver (5.3% vs 1.2%, p < .001) or a donation after cardiac death (7.2% vs 4.8%, P = .003) and less likely to receive a donation from a nationally shared donor (4.1% vs 10.6%, P < .001) ( Table 1) . 
LOS Over Time
All-Cause Graft Loss Over Time
Graft survival in older LT recipients also improved over time (Figure 2A) . One-year survival improved from 80% in 
Mortality Over Time
Survival in older LT recipients improved steadily over time ( Figure 2B ). One-year survival improved from 82% in 2003-06 to 91% in 2013-16; 3-year survival from 73% to 86%, and 5-year survival from 65% to 72% (Table 2) . After adjusting for donor, recipient, and transplantation factors, mortality in 2013-16 was 57% lower than in 2003-06 (aHR=0.43, 95% CI=0.38-0.49, P < .001) ( Table 3) . , there were significant decreases in acute rejection (aOR=0.70, P = .002), graft loss (aHR=0.46, P < .001), and mortality (aHR=0.43, P < .001) and shorter LOS (aOR=0.66, P < .001).
Our findings of a significant increase in the number of older adults undergoing LT are consistent with reports of increasing numbers of older adults undergoing kidney, heart, and lung transplantation. 30, 31 These studies describe a substantial rise in the number and proportion of older adults undergoing transplantation, with up to 18.4% of kidney transplant recipients aged 65 and older. 30 Our findings are also consistent with a report of increasing LT in recipients aged 60 and older. 2 We extended their study by evaluating trends over time in the characteristics and outcomes of older LT recipients and found that, despite the changing demographic characteristics, outcomes have dramatically improved. Also, the temporal improvement we observed in graft and recipient survival in older LT recipients is consistent with improvement in graft and recipient survival for older kidney transplant recipients, 30 supporting our hypothesis that improvements in immunosuppression might play a role. Finally, we found dramatic improvement in long-term outcomes of older LT recipients that is different from a recent study that showed no improvement in long-term outcomes for LT recipients of all ages; 32 that report did not stratify outcomes according to age, but the majority of LT recipients are younger than 65, so it would seem that younger recipients drove those results.
The strengths of this study include a large, unbiased, national cohort of LT recipients (every recipient in the United States) since implementation of the MELD allocation system. Although the general coarseness of comorbidity data in the national registry limited our study, it is unlikely that differences in comorbidities would explain the dramatic improvement observed in outcomes in recent years, especially given that older LT recipients are now sicker than those in the past (so any potential bias would be toward the null).
LT in older recipients increased dramatically in the last 15 years, with improvements in length of stay, acute rejection, graft survival, and recipient survival. Older adults with ESLD and their providers should be aware of these findings, and older age per se should not limit access to LT in older adults.
